Pharming GroupPHAR
About: Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.
Employees: 404
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
100% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 1
39% more capital invested
Capital invested by funds: $369K [Q3] → $514K (+$145K) [Q4]
20% more funds holding
Funds holding: 5 [Q3] → 6 (+1) [Q4]
0% more ownership
Funds ownership: 0.01% [Q3] → 0.01% (+0%) [Q4]
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
2 analyst ratings
HC Wainwright & Co. Joseph Pantginis 20% 1-year accuracy 82 / 412 met price target | $37 | Buy Reiterated | 21 Mar 2025 |
Oppenheimer Michael Carrier 20% 1-year accuracy 2 / 10 met price target | $39 | Outperform Maintained | 14 Mar 2025 |
Financial journalist opinion
Based on 3 articles about PHAR published over the past 30 days









